New research has revealed that once-weekly semaglutide one mg is a more cost-effective way to treat type 2 diabetes compared to insulin aspart.
During the study, long-term outcomes were projected over a person’s lifetimes using the IQVIA CORE Diabetes Model. SUSTAIN 11 was used to inform baseline cohort characteristics and treatment effects.
The participants were modelled to receive once-weekly semaglutide plus basal insulin for three years before intensifying to basal-bolus insulin, compared with basal-bolus insulin for lifetimes in the aspart arm.
Costs were accounted from a healthcare payer perspective in the UK, expressed in 2021 pounds sterling (GBP).
According to the results, once-weekly semaglutide 1 mg was associated with improvements in quality-adjusted life expectancy of 0.18 quality-adjusted life years versus insulin aspart, due to a reduced incidence and delayed time to onset of diabetes-related complications.
The results state: “Direct costs were estimated to be GBP 800 higher with semaglutide, with higher treatment costs partially offset by cost savings from avoidance of diabetes-related complications.
“Once-weekly semaglutide 1 mg was therefore associated with an incremental cost-effectiveness ratio of GBP 4457 per QALY gained versus insulin aspart.”
To access the entire study, click here.
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Once-weekly semaglutide is a ‘cost-effective’ treatment option for type 2 diabetes, study shows
JDRF appoints new chair
East Surrey Hospital awarded prestigious prize for hypo safety campaign
Six principles of good peer support for people with type 1 diabetes now available
Inpatient diabetes service survey launched
Former Apple designer to develop non-invasive glucose meter
Leicester Diabetes Centre create an ‘informative’ infographic to coincide with global campaign
New type 1 diabetes research has life-changing impact and gives hope of a cure
Latest diabetes technology showcased at national conference
How recent guidelines could help evolve the type 2 diabetes care landscape
Diabetes Specialist Nurse
Consultant in Diabetes and Endocrinology
Diabetes Support Worker (South West & South Central)
Digital Engagement Officer (South West & South Central)
Diabetic Specialist Midwife
Paediatric Diabetes Clinical Nurse Specialist & Transitional Care Lead
Diabetes Nurse Specialist
Diabetes Specialist Nurse – Community
Diabetes Specialist Nurse
Diabetes Specialist Nurse
This website is certified by Health On the Net Foundation. Click to verify.
The Diabetes Times © 2022


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *